It’s only fair to share… Ranolazine 雷诺嗪 MF C24H33N3O4 MW 427.536 Approvals FDA 2006, EMA 2008 for chronic angina Sponsor/Developer: Gilead Mechanism of action: Late sodium current inhibitor Indication (Phase): Type 2 diabetes (Phase III) A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone (currently recruiting participants …